BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
MAINZ, Germany, Feb. 22, 2017 -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at Cowen and Company’s 37th Annual Health Care Conference that is being held in Boston, MA from March 6 - 8, 2017. The presentation is scheduled for Tuesday, March 7 at 10:00 AM Eastern Standard Time.
Mr. Marett will provide an overview of the Company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations, a summary of its two most recent Nature publications related to its individualized mRNA cancer immunotherapeutics and the establishment of a GMP conform mRNA production facility at the Company´s headquarters in Germany.
About BioNTech AG
BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech´s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder. More information about BioNTech is available at www.biontech.com.
For meeting requests or further information, please contact: BioNTech AG Regina Jehle Tel: +49 6131 9084 1273 Email: [email protected] U.S. Media and Investor Inquiries: ICR, Inc. James Heins/Stephanie Carrington Tel. 203-682-8251 Tel. 646-277-1282 [email protected] [email protected] International Media & Investor Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68 [email protected]
